Galena’s NeuVax Mops Up Circulating Breast Cancer Cells To Prevent Metastases
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Median five-year data from the Phase I/II NeuVax trial released at ASCO this June showed that among node-positive patients 25.9% of the control had a recurrence, while metastases surfaced in only 5.6% of NeuVax patients. Final gold standard five-year data for all patients were released at the San Antonio Breast Cancer Symposium Dec. 5; Galena launched a Phase III trial in January 2012.